CR9439A - Metodos de disminuir la calcificacion - Google Patents

Metodos de disminuir la calcificacion

Info

Publication number
CR9439A
CR9439A CR9439A CR9439A CR9439A CR 9439 A CR9439 A CR 9439A CR 9439 A CR9439 A CR 9439A CR 9439 A CR9439 A CR 9439A CR 9439 A CR9439 A CR 9439A
Authority
CR
Costa Rica
Prior art keywords
calcification
decreasing
methods
individual
facet
Prior art date
Application number
CR9439A
Other languages
English (en)
Inventor
Martin David
Mariano Portillo Juan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR9439A publication Critical patent/CR9439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion porvee metodos para inhibir, disminuir o evitar la calcificacion vascular en un individuo, que incluye la administracion de una cantidad terapeuticamente efectiva de un compuesto calcimimetico al individuo. En una faceta, la calcificacion vascular puede ser calcificacion ateroesclerotica. En otra faceta, la calcificacion vascular puede ser calcificacion de la capa media.
CR9439A 2005-03-17 2007-10-16 Metodos de disminuir la calcificacion CR9439A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66327005P 2005-03-17 2005-03-17

Publications (1)

Publication Number Publication Date
CR9439A true CR9439A (es) 2007-11-23

Family

ID=36588866

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9439A CR9439A (es) 2005-03-17 2007-10-16 Metodos de disminuir la calcificacion

Country Status (15)

Country Link
US (1) US20060276534A1 (es)
EP (1) EP1858553A2 (es)
JP (1) JP2008533170A (es)
KR (1) KR20070116817A (es)
CN (1) CN101184508A (es)
AU (1) AU2006227429A1 (es)
BR (1) BRPI0609524A2 (es)
CA (1) CA2601669A1 (es)
CR (1) CR9439A (es)
EA (1) EA200701995A1 (es)
IL (1) IL185757A0 (es)
MX (1) MX2007011153A (es)
NO (1) NO20075304L (es)
WO (1) WO2006102061A2 (es)
ZA (1) ZA200707639B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507567A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
US20070248597A1 (en) * 2005-10-21 2007-10-25 Henley Charles M Iii Methods of decreasing vascular calcification using IL-1 inhibitors
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
KR20080055990A (ko) * 2005-11-22 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
KR20080110681A (ko) * 2006-04-20 2008-12-18 암겐 인코포레이티드 안정적 에멀젼 조제물
WO2007127445A2 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
CA2649245A1 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
EP1968932A1 (en) * 2006-11-20 2008-09-17 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
EP2433496A1 (en) * 2007-05-08 2012-03-28 Burnham Institute for Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
CN104168955A (zh) * 2011-11-10 2014-11-26 凯伊药品公司 拟钙剂及其使用方法
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
AU2019363816A1 (en) * 2018-10-25 2021-05-13 Eirgen Pharma Ltd. Methods of treatment with mixed metal compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
UA55374C2 (uk) * 1994-10-21 2003-04-15 Нпс Фармасьютікалз, Інк Сполуки, що мають активність по відношенню до рецепторів кальцію
ES2280460T3 (es) * 1996-05-01 2007-09-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
KR100771092B1 (ko) * 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
JP2002527414A (ja) * 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
EP1239837B1 (en) * 1999-10-19 2005-01-05 Genzyme Corporation Direct compression polymer tablet core
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment

Also Published As

Publication number Publication date
BRPI0609524A2 (pt) 2011-10-18
EP1858553A2 (en) 2007-11-28
US20060276534A1 (en) 2006-12-07
CN101184508A (zh) 2008-05-21
CA2601669A1 (en) 2006-09-28
NO20075304L (no) 2007-11-29
MX2007011153A (es) 2007-12-12
WO2006102061A3 (en) 2006-12-14
IL185757A0 (en) 2008-01-06
KR20070116817A (ko) 2007-12-11
AU2006227429A1 (en) 2006-09-28
EA200701995A1 (ru) 2008-02-28
WO2006102061A2 (en) 2006-09-28
ZA200707639B (en) 2008-06-25
JP2008533170A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
CR9439A (es) Metodos de disminuir la calcificacion
AP2373A (en) Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
CR10680A (es) Composiciones de inhibidores de chk1
HN2009001112A (es) Inhibidores de la actividad de la akt
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
NI200700320A (es) Inhibidores de la actividad akt
DK1869019T3 (da) Bicycliske [3.1.0]heteroarylamider som glycintransportinhibitorer type I
WO2006125616A3 (en) Pyrimidine-based cdk inhibitors for treating pain
DE602005023333D1 (de) Kinaseinhibitoren
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
ECSP067117A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
WO2006078752A3 (en) Inhibitors of dna methyltransferase
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
DE602007008954D1 (de) Scheibenbremsen-Abstandsscheibe
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
WO2007009606A3 (de) Desinfektionsmittel enthaltend eine kombination biozider und ein keratolytikum
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
PA8571901A1 (es) Nueva composicion farmaceutica
ES1058977Y (es) Candado para disco de freno de motocicletas.
WO2008057283A3 (en) Use of resolvins for inhibition of bone loss

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)